I hate trying to figure out what someone really means when they’re trying to be polite… tell me what they think I want to hear… or “spin” me on some idea or another.
There’s none of that here.
I’m writing to alert you that this is your first and maybe only opportunity to subscribe to Dave Lashmet’s Stansberry Venture Technology service without risking a penny on his research.
If you don’t act quickly, the opportunity may be gone.
But I also want to be clear: For most investors, this strategy is probably not right for you.
If you don’t understand how hard it is to decipher drug development research results – from tests on lab mice all the way through the final Phase III clinical trials… this isn’t for you.
If you’ve never thought about the work it takes traveling around the world – jetting to medical conferences, research labs, and talking with the head scientists, chief medical officers, and other executives… again, this service may not be for you.